Fusing MRI, CT, and PET Imaging Findings Automation Workflow

A custom multimodal fusion workflow automates the synthesis of MRI, CT, and PET findings, directly addressing the 15-30 minutes radiologists spend manually correlating disparate scans for complex cases. The business value comes from increased diagnostic throughput, reduced cognitive load, and faster preparation for multidisciplinary tumor boards. Implementation requires a multi-agent orchestration layer, typically built on frameworks like LangGraph, to manage specialized agents for semantic alignment, discrepancy resolution, and confidence scoring, all integrated with PACS and EHR systems via DICOM and HL7/FHIR APIs.

The architecture must include robust controls for data quality, exception routing, and human-in-the-loop review. Low-confidence alignments or significant discrepancies between modalities are automatically flagged and routed to a prioritized physician worklist within the RIS. Governance is enforced through detailed audit trails logging all AI inferences and clinician overrides. This creates a defensible, production-grade system that improves operational speed without compromising diagnostic safety or regulatory compliance, directly impacting departmental capacity and patient wait times.

This workflow automates the high-cognitive-load task of manually correlating disparate imaging findings, a bottleneck in multidisciplinary tumor board preparation and complex case review. The operational upside comes from reducing radiologist and oncologist synthesis time by 60-70% per case, accelerating diagnostic consensus and treatment planning. The architecture must integrate with PACS/VNAs for DICOM retrieval, employ specialized agents for modality-specific segmentation and feature extraction, and orchestrate a reasoning layer to resolve discrepancies before draft report assembly.

Implementation requires deploying containerized agents on a healthcare-grade Kubernetes cluster, with the orchestrator built using LangGraph or a custom state machine. The discrepancy engine uses rule-based logic and LLM-augmented reasoning to flag conflicts for human review. Controls include HIPAA-compliant data handling, audit trails for all overrides, and integration with existing clinical worklists via HL7/FHIR. Monitoring tracks fusion confidence scores, escalation rates, and end-to-end latency to ensure clinical safety and operational ROI.

This workflow automates the high-cognitive-load task of manually correlating disparate imaging findings, a bottleneck in multidisciplinary tumor board preparation and complex case review. By deploying specialized agents for each modality—each extracting semantic features and confidence scores—the system fuses evidence into a coherent narrative. The business value is direct: it reduces radiologist and oncologist synthesis time by 60-70% per complex case, accelerating treatment planning and improving consistency across readers. Implementation requires deep integration with PACS (e.g., Sectra, Intelerad) and EHRs (Epic, Cerner) for seamless data retrieval and report ingestion.

Architecturally, the core is a LangGraph-based orchestrator managing the extractor agents and a central reasoning engine that performs semantic alignment using ontology mapping (e.g., RadLex) and rules for resolving spatial and metabolic contradictions. Controls are critical: all low-confidence fused findings or major discrepancies are automatically routed to a prioritized review queue within the radiologist's worklist (e.g., Nuance PowerScribe). Each physician override is logged to an audit trail for model retraining and governance. Deployment is phased, starting with a pilot service line (e.g., neuro-oncology) to validate safety and workflow integration before scaling across the enterprise.

The core governance requirement is a closed-loop control system where AI-generated fused findings are never final until validated. Every unified diagnostic summary produced by the multi-agent reasoning layer must pass through a configurable approval gate before being committed to the EHR or presented at a tumor board. This gate is governed by a confidence score and clinical risk rules; low-confidence fusions or those flagging critical discrepancies are automatically routed to a subspecialist radiologist for review within the PACS worklist. This architecture ensures the AI acts as a force multiplier, not a replacement, directly addressing the operational bottleneck of synthesizing complex multi-modal cases while embedding safety.

Phased rollout mitigates risk and builds organizational trust. Phase 1 pilots the fusion and routing logic on a single service line (e.g., neuro-oncology) in shadow mode, comparing AI outputs to gold-standard reads without affecting clinical workflow. Phase 2 introduces the approval gate for non-critical findings, with all outputs still requiring final physician sign-off in the reporting system. Phase 3, informed by validated performance metrics, expands modality coverage and automates the drafting of unified summaries for tumor boards, integrating directly with systems like Epic and the tumor board management platform. Each phase is governed by a steering committee of radiologists, IT, and compliance to control scope, monitor exception rates, and approve progression.